St. Jude Looks Beyond Blood Pressure for Benefits of Renal Denervation

Fri, 02/15/2013 - 12:06pm
Mass Device

Medical device company St. Jude Medical launches a landmark study of its Enlightn renal denervation in order to find out whether the nerve ablating treatment has unexpected health benefits beyond lowering high blood pressure.

St. Jude Medical's EnliGHTen renal denervation system

St. Jude Medical (NYSE:STJ) is aiming to take its renal denervation therapy a step further, looking for signs that the minimally invasive treatment improves health beyond lowering high blood pressure in patients with uncontrolled hypertension.

The company's new Enlightnment trial is looking for long-term effects of renal denervation therapy, hoping to find out whether it reduces a patient's risk of major cardiovascular events.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.